INTRODUCTION
IRBP is a potent retinal-specific antigen that induces an experimental autoimmune uveoretinitis (EAU) in susceptible animals such as Lewis rats and monkeys [1] [2] [3] [4] [5] that resembles certain uveitic conditions in humans [6] , e.g. sympathetic ophthalmia and Vogt-Koyanagi-Harada disease [2] . Significant humoral [7] and/or cellular [8] immune responses against IRBP in patients have been reported. Thus, IRBP-induced EAU is thought to be a useful animal model for studying the pathogenesis of human uveitis.
Bovine IRBP has been fully sequenced, revealing that this protein consists of 1264 amino acid residues [9] . IRBP exhibits a four-fold repeat structure, developed by gene duplication some 600-800 million years ago [9, 10] , in which each segment is composed of approximately 300 residues. It has been reported that residues conserved in the evolutionary process are import-Correspondence: Dr Osamu Taguchi, Laboratory of Experimental Pathology, Aichi Cancer Centre Research Institute, Chikusa-ku, Nagoya 464, Japan. ant for various biochemical functions [9] . Recently, several peptides derived from bovine IRBP have been found to elicit EAU in Lewis rats [11] [12] [13] [14] . Among these peptides, the most potent immunopathogenic determinant is reported to be the sequence 1169-1191 [12] , which includes two immunogenic motifs common to T cell epitopes [15] . The residues comprising these motifs include GAAD (sequence 1175-1178) and GVVPD (1186-1190), and further investigation has shown that peptide 1179-1191 carries the full immunopathogenic capacity of the parent peptide [13] . Examination of the homologous residues between peptide 1179-1191 and its repeat peptides (271-283, 579-591 and 880-892) has shown that there are four homologous residues (1182W, 1186G, 1187V and 1189P). Kotake et al. reported that among these repeat peptides, peptides 271-283 and 880-892 were immunopathogenic, but that peptide 579-591 had no immunological activity [13] . However, a preliminary study we conducted revealed that peptide 579-591, which includes one immunogenic motif GWPD (586-590), possesses the ability to induce EAU in Lewis rats. In order to determine the most important residues for the induction of EAU and for immunodominance [16] , we investigated the following issues using IRBP-derived synthetic peptides: (i) which immunogenic motifs of peptide 1169-1191 are important?; (ii) do repeat peptides containing the homologous residues (W, G, V and P) elicit EAU?; (iii) do analogues of the peptides in which each of the homologous residues is substituted by other amino acids lose the ability to elicit EAU?; and (iv) do uveitogenic peptides produce autoantibodies? MATERIALS AND METHODS Antigens Bovine IRBP was purified according to the method described previously [17] . IRBP-derived peptides were synthesized using a model 431A peptide synthesizer (Applied Biosystems Inc., Foster City, CA) and were purified by reverse-phase high performance liquid chromatography (HPLC; Millipore Co. Ltd., Milford, MA). Identity of the peptide was confirmed by amino acid analysis and gas-phase sequencing. Concentration of the peptide solutions was determined by amino acid analysis. The synthetic peptides were denoted by the origin of their sequence [9] , followed by numbers indicating the positions of the first and last residues.
Animals
Male inbred Lewis rats, 6 weeks of age, were supplied by Clea Inc. (Tokyo, Japan).
Active immunization of rats and evaluation of EAU Rats were immunized with a single footpad injection of IRBP (50Iug) or one of the various synthetic peptides (0 5, 5 and 50 nmol) emulsified in Freund's complete adjuvant (FCA; Difco Labs., Detroit, MI) in a total volume of 0 1 ml. In addition, 1010 Bordetella pertussis bacteria (Wako Pure Chemicals, Osaka, Japan) were injected concurrently with the IRBP or the peptides. The development of EAU was detected by slitlamp biomicroscopy (Inami, Tokyo, Japan) performed on a daily basis. Severity was graded according to the intensity of ocular changes at 48 h after onset, using a scale of 0-8 ( Table 1 ). The eyes were enucleated under systemic anaesthesia with nembutal (Abbott Lab., North Chicago, IL) at 48 h or 21 Adoptive transfer of EA U Spleens from rats immunized with 50 jig of IRBP were collected 14 days after immunization. Spleen cells were cultured at 2 x 106 cells/ml in 2 ml of RPMI 1640 medium containing 10% FCS in 12-well cluster plates (Costar, Cambridge, MA) with or without stimulants (IRBP or peptides). After incubation for 3 days, the cells were harvested, and 7 x 107 to 1 1 x 107 cells were resuspended, then injected intraperitoneally into naive rats. Bordetella pertussis bacteria (1010 organisms) were also injected intravenously at the time of spleen cell transfer. The development of EAU was observed by slitlamp biomicroscopy and was assessed at 48 h after onset. The eyes were also examined histologically, as described above, to verify the development of EAU.
Antibody measurement Serum antibody levels were measured by ELISA. First, 96-well microtitre plates (Falcon, Becton Dickinson Labware, Lincoln Park, NJ) were coated with antigen (IRBP or peptides) at 3 ,g/ ml in a volume of 200 ,il/well. Serum samples from rats actively immunized with IRBP (50 tig/rat) were collected at 3-60 days after immunization to measure anti-IRBP antibody levels, and were added to the plates at dilutions of I:400 to 1: 12800. Serum samples from rats actively immunized with IRBP (50 Ag/ rat) or peptide (50 nmol/rat) were also collected to examine the antibody response to each peptide, and were added to the plates at dilutions of 1: 200 to 1: 6400. Peroxidase-conjugated goat anti-rat IgG (Cappel, Organo Teknika Corp., West Chester, PA) was used as the secondary antibody. Colour was developed by adding o-phenylendiamine in a buffer containing 001% H202, and was read at 492 nm with an ELISA autoreader (Corona, Tokyo, Japan). The data are presented as titres, determined as the highest serum dilution giving an absorption greater than 0 3 when compared with serum from untreated rats at an equivalent dilution.
RESULTS
Analysis of the immunopathogenic site in peptide 1169-1191 containing two immunogenic motifs As shown in Table 2 , active immunization of Lewis rats with peptide 1169-1191 induced severe EAU in all five rats, and strongly stimulated lymph node cells from Lewis rats immunized with IRBP. Peptide 1169-1191 includes two immunogenic motifs (GAAD and GWPD) common to T cell epitopes [15] . We synthesized two peptides containing one motif each ( Table 2 ). The amino terminal peptide (1169-1182) with the GAAD motif had no uveitogenicity and was not recognized by lymph node cells from rats immunized with IRBP. On the other hand, the carboxyl terminal peptide (1182-1191) containing the GVVPD motif elicited EAU in three of six rats, and was recognized by lymph node cells from rats immunized with IRBP. Furthermore, peptides with three extra residues at the amino or carboxyl terminus (peptides 1179-1191 and 1182-1194) elicited a higher incidence (100%) of EAU compared with the incidence (50%) by peptide 1182-1191, and also stimulated lymph node cells from rats immunized with IRBP ( Table 2) .
Examination of uveitogenicity and immunodominance of repeat peptides of sequence 1179-1191 As shown in Table 3 , active immunization of all repeat peptides of sequence 1179-1191 elicited EAU in Lewis rats, although the immunopathogenic dose, the incidence of EAU, and the degree of uveitogenicity varied. Figure 1 demonstrates the typical histological changes in the eyes of rats immunized with peptide 579-591. Similar inflammatory changes were also observed in specimens from rats immunized with peptide 880-892 as reported previously [13] . The histological changes in rats immunized with peptides 271-283 or 1179-1191 (50 nmol) were more severe than those induced by the other two repeat peptides (579-591 and 880-892), usually showing retinal detachment, accumulation of subretinal exudates, and destruction of the outer segment of the photoreceptor cell layer.
The immunodominance of the repeat peptides of sequence 1179-1191 was assessed in part by the capacity of the peptides to stimulate lymph node cells from Lewis rats immunized with IRBP. A vigorous response was observed by peptide 1179-1191, while low to no response was observed in cultures incubated with the other repeat peptides at a dose of 1 /M (Table 3) . A similar response pattern was observed over a wide *Spleen cells obtained from rats immunized with IRBP were cultured with each stimulant for 3 days, then injected into naive rats at doses of 7 x 107 to 11 x 107 cells. tConcentrations of stimulants: IRBP, 5 Mg/ml; peptides, 10 MM. tSpleen cells obtained from naive rats were cultured with IRBP for 3 days, then injected into naive rats at doses of 10 x 107 cells. from naive rats, when cultured with IRBP, did not induce EAU in other naive rats (Table 4 ).
Uveitogenicity and immunodominance of analogues of peptide 1182-1194 Table 5 shows the uveitogenicity and immunodominance of various analogues of peptide 1182-1194 which produced the most severe EAU among the peptides tested in this study ( Table 2 ). The analogue peptide with glycine substituted by leucine (L) at position 1186 (1186G -+ L) showed a reduced ability to elicit EAU, while three other analogues with the 414> Fig Adoptive transfer of EA U To examine the ability of cultured spleen cells from rats immunized with IRBP to induce EAU, such cells were transferred to naive rats. As shown in Table 4 , no EAU was induced in recipient rats by the injection of spleen cells cultured without antigen stimulation. However, spleen cells from the same rats could induce EAU in recipient rats when cultured not only with IRBP, but also with each of the peptides, with the exception of peptide 880-892 (Fig. 2 ). Histological changes in the eyes of recipient rats were generally similar to those of rats actively immunized with immunopathogenic peptides, while spleen cells Fig. 2 . Histological section of the retina of a rat that received a single injection of spleen cells (x 100). Degeneration of the retina was observed in the recipients. The spleen cells for transfer were obtained from rats immunized with IRBP, then cultured with peptide 579-591 for 3 days before injection. homologous residues substituted by glycine (G) (1182W -G, 1 187V -* G, and 1 189P -+ G) completely lost the ability to elicit EAU. Lymph node cells from rats immunized with IRBP did not recognize any of these analogues at doses of 0d-1I00/m, but did recognize the parent peptide (1182-1194).
Antibody production Serum antibodies against IRBP began to appear about 10 days after immunization with IRBP, and gradually increased in titre with time ( Fig. 3) . All sera collected from rats at 42 days after immunization with IRBP showed an antibody titre greater than 1: 6400 for IRBP ( Fig. 3 ), but did not react with most of the peptides tested (Fig. 4a ). Only two peptides (1182-1191 and 1182-1194) reacted with serum samples from the IRBPimmunized rats at a titre of 1: 200 (Fig. 4a ). On the other hand, most serum samples obtained from rats immunized with the peptides reacted with neither the individual peptides nor with IRBP (Fig. 4b) . Only the serum from one of six rats immunized with peptide 1169-1191 reacted slightly with both immunized peptide ( Fig. 4b ) and IRBP (data not shown) at titres of 1: 200 and 1: 400, respectively.
DISCUSSION
It has been reported that peptide 1169-1191 of IRBP is the most potent antigen in inducing EAU in Lewis rats [12] , and includes two immunogenic motifs (GAAD and GWPD) common to T cell epitopes [15] . In this study, we first analysed which motifs are important for the induction of EAU. We synthesized two peptides that contained one motif each. The inability of peptide 1169-1182 to elicit EAU in Lewis rats and to stimulate the proliferation of lymphocytes from rats immunized with IRBP, indicates that GAAD, the immunogenic motif [15] of peptide 1169-1191, does not play a role in the induction of EAU by IRBP. On the other hand, the other peptide containing the GVVPD motif, peptide 1182-1191, induced EAU and stimulated lymphocyte proliferation, indicating that the uveitogenic site of peptide 1169-1191 was localized at its calboxyl terminus. These results are in agreement with previously reported findings [12] . Compared with the incidence of EAU in rats immunized with peptide 1182-1191, the increased incidence of EAU following immunization with peptide 1179-1191 or 1182-1194 may be due to an increased affinity between these peptides and the MHC on antigenpresenting cells (APC) following the addition of three residues. In addition, we recently reported a type of chronic autoimmune uveoretinitis which develops spontaneously in BALB/c nude mice [17] after their T cell function is reconstituted by embryonic F344 rat thymus grafting [18] , and demonstrated that the target antigen inducing uveoretinitis in these mice is IRBP [17] . The lymphoid cells from the mice also responded to peptide 1182-1194, but not to peptide 1169-1 182 (our unpublished observations), indicating that in spite of differences in species and MHC molecules involved, both Lewis rats and BALB/c mice recognized the same or closely related residues of IRBP. An interesting finding was that peptide 579-591, which had no immunopathogenicity in a previous study [13] , elicited EAU in our current study ( Table 3 , Fig. 1 ). Thus, all the repeat peptides of sequence 1179-1191 that included the homologous residues elicited EAU. Another noteworthy finding was the ability of peptide 579-591 to generate uveitis in recipient rats without being able to stimulate lymphocyte proliferation in vitro (Table 4 ). Similar findings have been reported both in other EAU systems [19] [20] [21] and in models of experimental autoimmune encephalomyelitis (EAE) [22, 23] . The cause of this immune dissociation is not clear, but many authors have attributed it to a difference in T cell epitopes and T cell subsets involved in lymphocyte proliferation and adoptive transfer [19, [21] [22] [23] . Furthermore, it is also conceivable that differences in function of the APC in vivo and in vitro may produce this dissociation [20] .
All the repeat peptides of sequence 1179-1191 which contained the four homologous residues (W, G, V and P) elicited EAU. These peptides included three to five homologous residues of the important immunogenic motif (GVVPD). We substituted the four homologous residues with glycine (G) or leucine (L) in order to identify the essential residues in Lewis rats. Glycine is a small, non-charged amino acid that has been the residue of choice for many studies in which the function of residues [24, 25] and/or the activity of analogues have been investigated [26, 27] . The analogue peptides in which each of the homologous residues was substituted by glycine (1182W--G, 1187V--G, and 11 89P -* G) showed no ability to elicit EAU, while a leucinesubstituted analogue (1186G -L) showed a remarkably reduced ability to elicit EAU. Furthermore, all the analogues lost the capacity to stimulate lymph node cells obtained from rats immunized with IRBP (Table 5 ). These findings imply that all four homologous residues are indeed essential for the induction of EAU and for the property of immunodominance. Most rats immunized with IRBP had absent or quite low titres of antibodies against both the immunopathogenic and non-immunopathogenic peptides, although they all showed high antibody titres against IRBP (Fig. 4a ). Furthermore, few rats immunized with each peptide produced antibody to the peptide (Fig. 4b) , and most serum samples from these rats did not react with IRBP (data not shown). These findings taken together suggest that most of these immunopathogenic epitopes were not involved in antibody production, that EAU induced by these peptides progressed in the absence of autoantibody, and that other epitopes for antibody production may well exist in the IRBP molecule at locations other than these tested determinants.
